×
About 50 results

DAPA-CKD: SGLT2 Inhibitor Benefit Extends to Chronic Kidney Disease Without Diabetes
https://www.medscape.com/viewarticle/936550

Aug 29th, 2020 - Add patients with chronic kidney disease with or without diabetes to the growing list of people who get proven benefit from treatment with an SGLT2 inhibitor. Dr Hiddo Heerspink In the DAPA-CKD trial, treatment with the sodium-glucose cotransporter-2 (SGLT2) inhibitor dapagliflozin (Farxiga, AstraZeneca) cut the incidence of substantially worsened chronic kidney disease (CKD) by an average of 3...

Diabetes Drug Wins in HFrEF; Swift Shift to TAVR; Neurologists to Tackle HTN?
https://www.medpagetoday.com/cardiology/prevention/81708

Aug 20th, 2019 - The SGLT2 diabetes drug dapagliflozin (Farxiga) significantly reduced cardiovascular death and worsening of heart failure with reduced ejection fraction in topline results announced from the DAPA-HF trial among patients with and without type 2 diabetes. AstraZeneca called it a clinically meaningful effect. In the wake of TAVR's approval for low-risk patients, an industry analyst predicted a swi...

SGLT-2 Inhibitors May Not Raise UTI Risk, After All
https://www.medpagetoday.com/primarycare/diabetes/81313

Jul 30th, 2019 - SGLT-2 inhibitors were not associated with increased risk for severe urinary tract infections (UTI) versus other classes of antidiabetic therapies, according to a population-based cohort study. Compared with patients with type 2 diabetes initiating use of a DPP-4 inhibitor, new initiation of an SGLT-2 inhibitor didn't carry a increased risk for a severe UTI (hazard ratio 0.98, 95% CI 0.68-1.41)...

CREDENCE Shifts Our Thinking About SGLT2 Inhibitors
https://www.staging.medscape.com/viewarticle/914017

Jun 13th, 2019 - Today I'm going to discuss the CREDENCE trial: "Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy."[1] This is a very important trial because it starts shifting us to think about SGLT2 inhibitors as drugs that work to preserve renal function independently of things like glucose lowering or weight reduction. It's also a new way to start thinking about how to treat patients with...

CREDENCE Shifts Our Thinking About SGLT2 Inhibitors
https://www.medscape.com/viewarticle/914017

Jun 13th, 2019 - Today I'm going to discuss the CREDENCE trial: "Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy."[1] This is a very important trial because it starts shifting us to think about SGLT2 inhibitors as drugs that work to preserve renal function independently of things like glucose lowering or weight reduction. It's also a new way to start thinking about how to treat patients with...

Preemie PCI Device; HeartMate Trial Resuscitated; Repatha Access, Lawsuit
https://www.medpagetoday.com/cardiology/prevention/77413

Jan 13th, 2019 - FDA approved the Amplatzer Piccolo Occluder for patent ductus arteriosus in preemies and newborns weighing as little as 2 lbs. The smaller-than-a-pea transcatheter device is the first specifically approved for such infants, Abbott announced. The agency is giving tafamidis priority review for an indication in treating transthyretin amyloid cardiomyopathy (ATTR-CM), Pfizer announced. A decision i...

FDA Advisors: Tweak, Don't Dump CV Outcomes Trials
https://www.medpagetoday.com/cardiology/prevention/75938

Oct 25th, 2018 - SILVER SPRING, Md. -- A bare majority of FDA advisory committee members agreed that cardiovascular outcomes trials (CVOTs) to exclude harm by new type 2 diabetes drugs should continue to be required, but many on the panel called for the process to be streamlined. The key question was, "Should an unacceptable increase in cardiovascular risk be excluded" -- which so far has always been done throu...

Antisense Lp(a) Agent; Overdose Drug with AEDs; Mixed CV Results for T2D Drug
https://www.medpagetoday.com/cardiology/prevention/75425

Oct 1st, 2018 - The antisense apolipoprotein A inhibitor AKCEA-APO(a)-LRx significantly reduced Lp(a) compared with placebo in topline results released from a phase II trial among patients with cardiovascular disease and high Lp(a). (BioSpace) Automated external defibrillator cabinets in VA facilities will now also house naloxone (Narcan) for opioid overdose reversal. (NPR) The SGLT2 inhibitor dapagliflozin (F...

Weight Gain After Smoking Cessation Hikes Diabetes Risk -- But Not to Worry
https://www.medpagetoday.com/pulmonology/smoking/74583

Aug 15th, 2018 - Although weight gain associated with smoking cessation is a genuine risk factor for developing diabetes, the increase is temporary and the benefits of quitting far outweigh the metabolic risks, researchers said. Diabetes risk peaked 5 to 7 years after quitting smoking and then gradually decreased in a cohort study appearing in New England Journal of Medicine. "We have known that diabetes risk i...

Brugada Genes Debunked; T2D Drug Excuses; Paradise Pivotal Trial
https://www.medpagetoday.com/cardiology/prevention/73911

Jul 8th, 2018 - A study reevaluating genes reported to be associated with Brugada syndrome challenged the validity of all but one. (Circulation) The American College of Cardiology renamed its ACTION Registry under the National Cardiovascular Data Registry umbrella to the Chest Pain - MI Registry, with a broader population to include unstable and low-risk angina. There are too many excuses for cardiologists not...

Hypertension in Pregnancy May Foretell Lifetime of Problems
https://www.medpagetoday.com/cardiology/hypertension/73820

Jul 2nd, 2018 - Hypertensive disorders during pregnancy were linked with increased rates of chronic hypertension, hypercholesterolemia and type 2 diabetes later in life, researchers found from a large prospective study. Nurses Health Study II participants with either gestational hypertension or preeclampsia during their first pregnancies had higher rates of all three later on -- often beginning soon after birt...

ACP Recommends Less-Intensive HbA1c Target for T2D
https://www.medpagetoday.com/primarycare/diabetes/71539

Mar 5th, 2018 - Action Points New type 2 diabetes guidelines from the American College of Physicians (ACP) recommend less-intensive blood sugar control for most patients, and suggest a target glycated hemoglobin (HbA1c) level between 7% and 8% for most patients. Note that studies have not consistently shown that intensive glycemic control to HbA1c levels below 7% reduces clinical microvascular events, or reduc...

ACP Recommends Less-Intensive HbA1c Target for T2D
https://www.medpagetoday.com/primarycare/diabetes/71539?comment=true

Mar 5th, 2018 - Action Points New type 2 diabetes guidelines from the American College of Physicians (ACP) recommend less-intensive blood sugar control for most patients, and suggest a target glycated hemoglobin (HbA1c) level between 7% and 8% for most patients. Note that studies have not consistently shown that intensive glycemic control to HbA1c levels below 7% reduces clinical microvascular events, or reduc...

Hyperkalemia Linked to Poor Outcomes in Diabetes Patients
https://www.staging.medscape.com/viewarticle/886072

Sep 21st, 2017 - LISBON, PORTUGAL — Elevated potassium is common and associated with poor outcomes in a real-world population of patients with diabetes, new research finds. Results from the Danish population-based cohort study were presented September 15 here at the European Association for the Study of Diabetes (EASD) 2017 Annual Meeting by Reimar W Thomsen, MD, PhD, of Aarhus University, Copenhagen, Denmark. ...

Hyperkalemia Linked to Poor Outcomes in Diabetes Patients
https://www.medscape.com/viewarticle/886072

Sep 21st, 2017 - LISBON, PORTUGAL — Elevated potassium is common and associated with poor outcomes in a real-world population of patients with diabetes, new research finds. Results from the Danish population-based cohort study were presented September 15 here at the European Association for the Study of Diabetes (EASD) 2017 Annual Meeting by Reimar W Thomsen, MD, PhD, of Aarhus University, Copenhagen, Denmark. ...

FDA Panel Says Yes to CV Indication for Liraglutide
https://www.medpagetoday.com/cardiology/prevention/66160

Jun 20th, 2017 - SILVER SPRING, MD -- An FDA advisory committee voted 17-2 on Tuesday that the diabetes drug liraglutide (Victoza) appeared to reduce cardiovascular risk in patients with type 2 diabetes, but expressed concern about which groups the finding applied to. The Endocrinologic and Metabolic Drugs Advisory Committee also voted 19-0 that the drug's use in type 2 diabetes patients did not result in exces...

ACP Highlights 2014's Top Studies
https://www.medpagetoday.com/primarycare/generalprimarycare/51319

May 1st, 2015 - BOSTON -- What were the most significant findings in 2014? If you're a cardiologist, new therapies and new uses for old therapies. If you're a geriatrician, chipping away at polypharmacy. If you're a general internist, guidelines. The Annals of Internal Medicine published summaries from nine fields, with sessions for each at the American College of Physicians' annual meeting underway here. Card...

FDA: No Clear Sign of Harm With Olmesartan in Diabetics
https://www.medpagetoday.com/cardiology/hypertension/46494

Jun 25th, 2014 - The evidence linking use of the angiotensin II receptor blocker (ARB) olmesartan in patients with diabetes and increased cardiovascular risk is not conclusive, according to a completed FDA safety review. The agency said that it believes the benefits of using the drug outweigh the risks, adding that recommendations for use will not change. Information from some of the studies addressing the pote...

Diet Key in CVD, Diabetes Risks
https://www.medpagetoday.com/cardiology/diabetes/46340

Jun 15th, 2014 - Action Points Note that one of the studies was published as an abstract and presented at a conference. Those data and conclusions should be considered to be preliminary until published in a peer-reviewed journal. Dietary choices play an important role in controlling cardiovascular risk in patients with type 2 diabetes and in influencing the risk of developing diabetes in the first place, two st...

Friday Feedback: JNC 8 in Practice
https://www.medpagetoday.com/cardiology/hypertension/43547

Dec 20th, 2013 - Friday Feedback is a feature that presents a sampling of opinions solicited by MedPage Today in response to a healthcare issue, clinical controversy, or new finding reported in the previous week. This week, the topic is the new hypertension treatment guideline, JNC 8. Participants were contacted by email and asked to respond to the following question: What is your view of these guidelines and w...